Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Key protein identified as cause of aggressive prostate cancer

Key protein identified as cause of aggressive prostate cancer

News Releases Nov 25, 2016 3 minutes

News Release from Vancouver Coastal Health and the University of British Columbia

VCH and UBC researchers identify gene linked to growth of aggressive neuroendocrine prostate cancer.

Researchers at the Vancouver Prostate Centre (VPC) have identified the key protein linked to Neuroendocrine Prostate Cancer (NEPC). NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy. Androgen deprivation therapy is a cornerstone of prostate cancer treatment. Since prostate cancers rely on androgen as a fuel for growth, the treatments target the androgen receptor and starve the cancer cells of hormones. Despite initial good responses, progression to treatment-resistant prostate cancer is common including the emergence of an aggressive variant called treatment-induced NEPC.

Dr. Amina Zoubeidi, a research scientist at the Vancouver Coastal Health Research Institute and an associate professor in the Department of Urologic Sciences at UBC, says the discovery of the protein driving the emergence of NEPC is a timely and important one. As more prostate cancer patients are treated with anti-androgen drugs, the number of cases of NEPC is growing. 

We estimate between 12 to 20 per cent of patients treated with second line androgen deprivation therapy go on to develop NEPC. These are significant numbers. Up until now we weren’t able to answer why these cells were becoming so aggressive in some patients. Now we have an answer.

Dr. Zoubeidi and her team of researchers made the discovery using a two-step process. They first designed a lab model using mice to mimic the growth of NEPC. This model helped them identify a key protein called BRN2 that was essential for NEPC to develop. The researchers then went on to study human tissue samples from patients with NEPC. They found that BRN2 was also highly expressed in those samples.

Dr. Zoubeidi says the team then used new genome editing CRISPR technology, to turn off the BRN2 gene. When they did so, they prevented the emergence of NEPC. 

The BRN2 discovery has been published in the journal Cancer Discovery and has been highlighted in Nature Reviews Urology.

Next Steps

Dr. Zoubeidi says researchers at VPC are wasting no time in moving to the next step, and acting on their findings. They are already working to develop an inhibitor drug that could turn off BRN2 in prostate cancer patients and block the growth of NECP. 

“Prostate cancer is a leading cause of death for men in Canada and worldwide. At VPC, we are not only able to identify the cause of this aggressive type of prostate cancer but we are already hard at work to find a drug to block it. We’re working fast because we are committed to improving outcomes for patients. I feel confident that we will make more breakthroughs,” says Dr. Zoubeidi.

 

Researchers

Amina Zoubeidi

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Vancouver Prostate Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Stories

Computer-aided detection and diagnosis of colorectal cancer

May 19, 2023 cancer, technology, gastrointestinal
Type
Stories

Ask an expert: How can I reduce my risk of developing skin cancer?

May 16, 2023 skin, sun, preventative
Type
Stories

Celebrating 20 years of innovation and excellence in research at VCHRI

May 10, 2023 knowledge translation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy